Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 7/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.37 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | PRKX | P51817 | 1/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10303339 | 0.94 | MAOB (0.37) | F10MAOBGRM5FFAR1MAOA | |
| SCHEMBL12907723 | 0.93 | FFAR1 (0.37) | F10MAOBGRM5FFAR1MAOA | |
| SCHEMBL13586513 | 0.88 | F10 (0.38) | F10MAOBGRM5FFAR1MAOA | |
| SCHEMBL12907023 | 0.88 | GYS1 (0.39) | MAOBFFAR1S1PR1FFAR4 | |
| SCHEMBL12908518 | 0.87 | FFAR4 (0.36) | MAOBFFAR1MAOAFFAR4 | |
| SCHEMBL12908284 | 0.85 | FFAR1 (0.40) | F10MAOBFFAR1NAAA | |
| SCHEMBL13586515 | 0.84 | FFAR1 (0.39) | F10MAOBGRM5FFAR1MAOA | |
| SCHEMBL12822769 | 0.84 | FFAR1 (0.43) | F10MAOBFFAR1 | |
| SCHEMBL12823794 | 0.84 | FFAR4 (0.37) | MAOBFFAR1FFAR4 | |
| SCHEMBL12823408 | 0.84 | FFAR4 (0.37) | MAOBFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
| WO-2009125668-A1 | TRICYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | チッソ株式会社 (JP) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | F10 737/4885MAOB 3725/4885GRM5 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.